Phaseline

Targets › FST

FST (Follistatin): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Other; next expected readout Sep 2027.

Multifunctional regulatory protein whose primary function is to antagonize members of the transforming growth factor beta (TGF-beta) superfamily including activin, myostatin, GDF11 or bone morphogenetic proteins (BMPs). Mechanistically, binds to these ligands in the extracellular space, blocking their type II receptor-binding site to inhibit downstream signaling. (UniProt, P19883)

Open in Phaseline: the race on FST, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Unlimited BiotechnologyAAV9-Follistatin gene therapy
Adeno-associated virus serotype 9 vector encoding human follistatin to increase muscle mas
FSTPhase 1Age-related Muscle DeclineSep 2027

Conditions

Age-related Muscle Decline (1)

Modalities

other (1)

Companies

Unlimited Biotechnology (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.